Tech Company Financing Transactions
TORL BioTherapeutics Funding Round
TORL BioTherapeutics closed a $158 million Series B financing round on 4/10/2024. Backers included Deep Track Capital, Avidity Partners and Blue Owl Capital.
Transaction Overview
Company Name
Announced On
4/10/2024
Transaction Type
Venture Equity
Amount
$158,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to continue the clinical development of TORL-1-23, its ADC to treat CLDN 6+ tumors, through Phase 1 and a pivotal Phase 2 trial that will start in the second half of 2024. Proceeds will also be used to fund the on-going Phase 1 studies for the TORL-2-307 program, both a monoclonal antibody (mAb) and an ADC, for the treatment of CLDN 18.2+ solid tumors, TORL-3-600, an ADC for the treatment of CDH17+ colorectal cancer, and TORL-4-500, an ADC for the treatment of Delta like non-canonical Notch Ligand 1 (DLK1) positive solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Los Angeles, CA Undisclosed
USA
Los Angeles, CA Undisclosed
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
TORL BioTherapeutics is a clinical-stage bi ©pharmaceutical business. Operator of a drug development company intended to accelerate pre-clinical drug discovery. The company offers combined UCLA's slamon drug screening with Caltech's Stoltz chemistry platform in order to identify targets with clinical success, enabling researchers to develop proprietary drugs with unique and optimized profiles.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Licata
Co-Founder
Mark Alles
Co-Founder
Dennis Slamon
Browse more venture capital transactions:
Prev: 4/10/2024: HysetCo venture capital transaction
Next: 4/10/2024: ELIAS Animal Health venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record tech company VC transactions. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs